Quick Facts

• Addresses symptoms: Used to manage symptoms experienced during and after menopause, such as hot flushes and vaginal dryness.
• Bone health: May be considered for reducing the risk of bone mineral density loss in postmenopausal individuals who are at high risk of fracture.

---

What Renorma Treats: Main Uses and Benefits

Renorma is a prescription medication utilized in postmenopausal individuals. It is intended to substitute for the reduction of estrogen production that occurs after menopause, which may contribute to managing various associated physical changes.

One primary indication for Renorma is to help alleviate vasomotor symptoms and other changes that occur as a result of a natural or surgical menopause. These symptoms may include hot flushes and discomfort related to vaginal atrophy, such as dryness or irritation.

In addition to addressing menopausal symptoms, Renorma is also an available option for the prevention of postmenopausal bone mineral density loss (osteoporosis). This use is generally reserved for individuals at elevated risk of fractures who may not be able to use other treatments to help maintain bone density. Consistent use, as directed by a healthcare professional, may help contribute to overall patient well-being and symptom management.

Eligibility for Renorma

Renorma is officially indicated only for postmenopausal women. For women who experience natural menopause, regulatory labeling specifies that treatment should not begin until at least 12 months after their last natural period. Women who have had a surgical menopause may be eligible to commence treatment immediately.

Contraindications (Who Must Not Use Renorma)

Official regulatory documents list several absolute contraindications, meaning the medicine must not be used under these conditions:

• Known or suspected cancers: This includes known past or suspected breast cancer and other known or suspected estrogen-dependent malignant tumors (e.g., endometrial cancer).
• Bleeding and Endometrial Health: Individuals with undiagnosed genital bleeding or untreated endometrial hyperplasia are excluded.
• Blood Clotting Disorders: Use is strictly prohibited for patients with a history of or current venous thromboembolism (e.g., DVT or pulmonary embolism) or any history of arterial thromboembolic disease (e.g., heart attack, stroke, or TIA).
• Liver and Metabolic Health: The drug is contraindicated in cases of acute liver disease or if liver function tests have failed to return to normal after prior liver disease, and for those with Porphyria.
• Sensitivity and Pregnancy: The drug must not be used if there is a known hypersensitivity to its components, or during pregnancy and lactation.

Interactions with other medicines and products

The official regulatory profile for Renorma (Tibolone) documents several interaction patterns, primarily affecting the drug's exposure or the activity of co-administered agents. These documented patterns establish specific management and restriction requirements.

Interacting Agents	Classification	Official Outcome and Restriction
Oral Anticoagulants (e.g., Warfarin, Acenocoumarol)	Pharmacodynamic Interaction	Enhanced anticoagulant effect; requires frequent monitoring of coagulation status (INR).
Hepatic Enzyme Inducers (e.g., Rifampicin, Phenytoin, Carbamazepine)	Pharmacokinetic Interaction	Reduction in plasma concentrations of Renorma, leading to decreased therapeutic efficacy.
Herbal Product (St John’s Wort)	Pharmacokinetic Interaction	May reduce the overall effectiveness of Renorma.

The regulatory basis establishes that co-administration with enzyme-inducing medicines and St John's Wort is officially associated with a clinically relevant reduction in the medicine's effectiveness.

Furthermore, a specific procedural constraint is noted in the regulatory labeling due to the risk of venous thromboembolism (VTE) documented for the drug. Consideration should be given to temporarily stopping the use of this medicine approximately 4 to 6 weeks before any major elective surgical procedure. This measure is a required part of the drug's official risk-management profile for the surgical context.

This interaction structure is defined by effects on drug metabolism and coagulation activity, establishing requirements for careful management when co-administered.

Renorma (Tibolone) is a synthetic steroid that is rapidly metabolized into three primary active compounds: 3alpha-hydroxytibolone, 3beta-hydroxytibolone, and the Delta4-isomer of tibolone. This mechanism results in tissue-selective hormonal activity.

In tissues like bone, the 3alpha- and 3beta-hydroxy metabolites function as agonists at estrogen receptors (ERs), promoting bone-mass preservation via intracellular signaling cascades. Similarly, in the thermoregulatory centers of the brain and in vaginal tissue, these metabolites also act as ER agonists.

Conversely, in the endometrium, the Delta4-isomer acts as an agonist at progesterone receptors (PRs). Simultaneously, local tissue enzymatic modulation occurs, where tibolone and its metabolites inhibit sulfatase and 17beta-hydroxysteroid dehydrogenase (HSD) Type I, while stimulating sulfotransferase and 17beta-HSD Type II. This collective enzymatic modification and PR agonism leads to attenuated proliferation of the endometrium. The Delta4-isomer also possesses androgenic agonist activity at androgen receptors, which contributes to system-level modulation.

The administration of Renorma (tibolone) follows a standardized protocol defined in regulatory prescribing information. It is formulated as a single oral tablet that is taken as a fixed, non-titrated daily dose. This fixed regimen establishes a highly specific administration pattern, differentiating it from traditional hormone therapies.

Core Usage Protocol

Usage Component	Official Labeled Instruction
Route and Strength	Oral administration; 2.5 mg tablet.
Schedule and Frequency	Taken once daily in a continuous, non-cyclical regimen. A separate progestogen is not required.
Initiation Timing	Treatment must be initiated at least 12 months after the individual's last natural menstrual bleed.
Administration	The tablet should be swallowed whole with water, preferably at the same time every day.

Handling of Timing and Duration

The instructions define specific procedures for proper time adherence. If a dose is missed, it should be taken immediately only if the delay is less than 12 hours from the usual time. If the missed dose is 12 hours or more overdue, the tablet should be skipped entirely, and the continuous daily schedule should be resumed with the next planned dose.

Dosing guidelines confirm no specific dosage adjustment is necessary for older adults. However, a major constraint for use is the established contraindication in individuals with severe hepatic impairment. Furthermore, the overall duration of the treatment is subject to periodic re-evaluation, with the prescribing professional instructed to review the necessity of continued use at least annually.

Research evidence / Overview of studies for Renorma

Evidence for Use in Managing Postmenopausal Symptoms

The primary body of evidence for Renorma comes from Randomized Controlled Trials (RCTs) which explored how symptoms change over defined time intervals. These studies, along with systematic reviews synthesizing their results, generally included postmenopausal women reporting symptoms like hot flushes, sweating, and local discomfort related to vaginal atrophy. These trials specifically monitored outcomes related to physical discomfort and used validated scales to track the daily frequency and severity of hot flushes.

Studies tracking the core symptoms report how symptoms evolved in the observed populations. For frequent, disruptive symptoms like hot flushes, the findings describe patterns observed in the studies where reported severity and frequency were tracked over short- to intermediate-term follow-up periods (typically 3 months to 3 years). Research related to vulvovaginal symptoms also described patterns observed in the studies regarding self-reported vaginal dryness and changes in specific physiological markers measured in the tissue.

Evidence for Use in Preventing Bone Mineral Density Loss

Renorma was studied for its potential role in skeletal health, with evidence drawn from large, controlled trials that tracked patients over moderate to long periods. These studies focused on outcomes related to systemic or functional imbalance, primarily the loss of bone mineral density (BMD) in postmenopausal women. Researchers monitored changes in BMD at key skeletal sites, such as the hip and spine, typically via specialized scans. The longest-running trials also research examined the long-term pattern related to the occurrence of fractures.

In these trials, comparing the study group to those receiving a placebo, the data show patterns related to the maintenance or measured increase of BMD over a two- to three-year period. A key limitation here is that results apply only to the populations studied, which often included older postmenopausal women with pre-existing low bone mass or established osteoporosis. Data for certain groups remain insufficient when attempting to draw conclusions about fracture prevention in younger postmenopausal women who are otherwise low-risk.

Key Studies & References

1. Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women (RCT)

Common questions about Renorma (FAQ)

---

Q: What is Renorma and what is it used for?

Renorma is a medicine that contains the active ingredient tibolone. It is a type of Hormone Replacement Therapy (HRT).

It is used to relieve the symptoms that occur after menopause (the permanent end of menstrual periods, or "change of life") in women who are at least 12 months post-menopause. Symptoms may include hot flashes, night sweats, and vaginal dryness.

It is also used to prevent osteoporosis (bone thinning) in postmenopausal women who are at high risk of fractures and who cannot take other medicines for osteoporosis.

---

Q: How should I take Renorma?

The recommended dose is one tablet (2.5 mg) once daily.

• Take the tablet at about the same time each day.
• Swallow the tablet whole with some water.
• Do not chew or crush the tablet.

If you miss a dose, take it as soon as you remember, unless it is more than 12 hours overdue. In that case, skip the missed dose and take the next dose at your usual time. Do not take a double dose to make up for a missed tablet.

---

Q: Who should not take Renorma?

Do not take Renorma if any of the following apply to you:

• If you are pregnant or breastfeeding.
• If you have ever had a blood clot (thrombosis) in a vein (such as in the legs or lungs).
• If you have or have had breast cancer or any other cancer that is sensitive to estrogens, such as cancer of the lining of the womb (endometrial cancer).
• If you have abnormal vaginal bleeding that has not been investigated by your doctor.
• If you have or have had a liver disease and your liver function tests have not returned to normal.
• If you have a rare inherited blood disorder called porphyria.
• If you have an allergy to tibolone or any of the other ingredients in this medicine.

---

Q: Can Renorma be taken with other medicines?

Renorma may interact with certain other medicines, which could affect how well either medicine works or increase the risk of side effects. It is important to tell your doctor or pharmacist about all the medicines you are taking, including over-the-counter medicines, vitamins, and herbal supplements.

Of particular note, Renorma may enhance the effects of blood-thinning medicines such as warfarin. If you take both, your doctor may need to monitor your blood and adjust the dose of your anticoagulant.

---

Q: What are the possible side effects of Renorma?

Like all medicines, Renorma can cause side effects, although not everyone gets them. Common side effects (may affect up to 1 in 10 people) include:

• Vaginal bleeding or spotting (especially during the first few months of treatment)
• Stomach pain
• Abnormal hair growth
• Acne
• Vaginal discharge or itching
• Breast tenderness

Less common but serious side effects include an increased risk of developing:

• Blood clots in the veins (venous thromboembolism)
• Stroke
• Breast cancer
• Cancer of the lining of the womb (endometrial cancer)

If you experience any signs of a serious side effect, such as sudden chest pain, shortness of breath, or sudden severe headache, you should seek immediate medical attention.

---

Storage Conditions

Renorma (tibolone) must be stored strictly according to the official labeling requirements to maintain its stability and effectiveness. The product must be kept at a temperature below 30 C and must not be refrigerated or frozen. The tablets must be stored in the original container and outer carton, which is required to protect the medicine from light and moisture.

Furthermore, to ensure safety, the medication must be kept out of the sight and reach of children, as explicitly stated in the official documentation.

Disposal Instructions

Disposal of unused or expired Renorma tablets must be handled responsibly. Regulatory instructions advise that the product should not be thrown away via wastewater or household waste. Instead, unused medication and waste material must be disposed of in accordance with local regulations and pharmacy take-back programs.